Characterization of a Panel of Monoclonal Antibodies Targeting the F-Protein of the Respiratory Syncytial Virus (RSV) for the Typing of Contemporary Circulating Strains

被引:0
|
作者
Krivitskaya, Vera [1 ]
Petrova, Ekaterina [1 ]
Sorokin, Evgeniy [1 ]
Tsareva, Tatyana [1 ]
Sverlova, Maria [1 ]
Komissarova, Kseniia [1 ]
Sominina, Anna [1 ]
Danilenko, Daria [1 ]
机构
[1] WHO Natl Influenza Ctr, Minist Hlth Russian Federat, Smorodintsev Res Inst Influenza, St Petersburg 197376, Russia
关键词
respiratory syncytial virus; contemporary circulating strains; F protein; monoclonal antibody; escape mutant; fixed cell-ELISA; immunoblotting; neutralization activity; FUSION PROTEIN; ANTIGENIC CHARACTERIZATION; MOLECULAR EVOLUTION; GROUP-A; PALIVIZUMAB; INFECTIONS; PREVENTION; RESISTANT; EPITOPES; BURDEN;
D O I
10.3390/tropicalmed9010001
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Respiratory syncytial virus (RSV) is the most common cause of upper and lower respiratory tract infections in infants and young children. Virus-specific monoclonal antibodies (mAbs) can be used for diagnosis, prophylaxis, and research of RSV pathogenesis. A panel of 16 anti-RSV mAbs was obtained from mice immunized by RSV strain Long. Half of them had virus-neutralizing activity. According to Western blot all of these mAbs effectively bound native oligomeric (homodimeric and homotrimeric) forms of the RSV fusion (F) protein. Only five of the mAbs interacted with the monomeric form, and only one of these possessed neutralizing activity. None of these mAbs, nor the commercial humanized neutralizing mAb palivizumab, reacted with the denaturated F protein. Thus, interaction of all these mAbs with F protein had clear conformational dependence. Competitive ELISA and neutralization assays allowed the identification of nine antigenic target sites for the interaction of mAb with the F protein. Five partially overlapping sites may represent a complex spatial structure of one antigenic determinant, including one neutralizing and four non-neutralizing epitopes. Four sites (three neutralizing and one non-neutralizing) were found to be distinct. As a result of virus cultivation RSV-A, strain Long, in the presence of a large amount of one of the neutralizing mAbs, an escape mutant with a substitution, N240S, in the F protein, was obtained. Thus, it was shown for the first time that position 240 is critical for the protective effect of an anti-RSV antibody. To assess the ability of these mAbs to interact with modern RSV strains circulating in St. Petersburg (Russia) between 2014 and 2022, 73 RSV-A and 22 RSV-B isolates were analyzed. Six mAbs were directed to conserved epitopes of the F protein as they interacted most efficiently with both RSV subtypes in a fixed cell-ELISA and could be used for diagnostic assays detecting RSV.
引用
收藏
页数:14
相关论文
共 50 条
  • [31] The Respiratory Syncytial Virus (RSV) G Protein Enhances the Immune Responses to the RSV F Protein in an Enveloped Virus-Like Particle Vaccine Candidate
    Cullen, Lori McGinnes
    Luo, Bin
    Wen, Zhiyun
    Zhang, Lan
    Durr, Eberhard
    Morrison, Trudy G. G.
    JOURNAL OF VIROLOGY, 2023, 97 (01)
  • [32] Respiratory syncytial virus (RSV) fusion protein subunit F2, not attachment protein G, determines the specificity of RSV infection
    Schlender, J
    Zimmer, G
    Herrler, G
    Conzelmann, KK
    JOURNAL OF VIROLOGY, 2003, 77 (08) : 4609 - 4616
  • [33] IMMUNODOMINANT T-CELL EPITOPE ON THE F-PROTEIN OF RESPIRATORY SYNCYTIAL VIRUS RECOGNIZED BY HUMAN-LYMPHOCYTES
    LEVELY, ME
    BANNOW, CA
    SMITH, CW
    NICHOLAS, JA
    JOURNAL OF VIROLOGY, 1991, 65 (07) : 3789 - 3796
  • [34] Immunoglobulin A, immunoglobulin G, and neutralizing antibodies to respiratory syncytial virus increase in human milk following immunization with an RSV F protein vaccine
    Shakib, J. H.
    Varner, M. W.
    Fiuza, M.
    Trenholme, A. A.
    Baqui, A.
    Frech, S.
    Glenn, G.
    Smith, G.
    Patel, N.
    Fries, L.
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2019, 221 (06) : 669 - 670
  • [35] Comparative effects of two neutralizing anti-respiratory syncytial virus (RSV) monoclonal antibodies in the RSV murine model:: Time versus potency
    Mejías, A
    Chávez-Bueno, S
    Ríos, AM
    Aten, MF
    Raynor, B
    Peromingo, E
    Soni, P
    Olsen, KD
    Kiener, PA
    Gómez, AM
    Jafri, HS
    Ramilo, O
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (11) : 4700 - 4707
  • [36] Molecular characterization of human respiratory syncytial virus strains circulating among hospitalized children in Jordan
    Khasawneh, Ashraf I.
    Himsawi, Nisreen
    Sammour, Ashraf
    Abu Safieh, Hazem
    Burayzat, Salma
    Al-Momani, Hafez
    Alotaibi, Moureq R.
    Al Shboul, Sofian
    Saleh, Tareq
    BMC INFECTIOUS DISEASES, 2024, 24 (01)
  • [37] Immunogenicity and safety of a respiratory syncytial virus fusion protein (RSV F) nanoparticle vaccine in older adults
    Louis Fries
    Vivek Shinde
    Jeffrey J. Stoddard
    D. Nigel Thomas
    Eloi Kpamegan
    Hanxin Lu
    Gale Smith
    Somia P. Hickman
    Pedro Piedra
    Gregory M. Glenn
    Immunity & Ageing, 14
  • [38] Immunogenicity and safety of a respiratory syncytial virus fusion protein (RSV F) nanoparticle vaccine in older adults
    Fries, Louis
    Shinde, Vivek
    Stoddard, Jeffrey J.
    Thomas, D. Nigel
    Kpamegan, Eloi
    Lu, Hanxin
    Smith, Gale
    Hickman, Somia P.
    Piedra, Pedro
    Glenn, Gregory M.
    IMMUNITY & AGEING, 2017, 14
  • [39] Electron microscopy of the human respiratory syncytial virus fusion protein and complexes that it forms with monoclonal antibodies
    Calder, LJ
    González-Reyes, L
    García-Barreno, B
    Wharton, SA
    Skehel, LJ
    Wiley, DC
    Melero, JA
    VIROLOGY, 2000, 271 (01) : 122 - 131
  • [40] Combination Therapy Using Monoclonal Antibodies against Respiratory Syncytial Virus (RSV) G Glycoprotein Protects from RSV Disease in BALB/c Mice
    Caidi, Hayat
    Harcourt, Jennifer L.
    Tripp, Ralph A.
    Anderson, Larry J.
    Haynes, Lia M.
    PLOS ONE, 2012, 7 (12):